A Phase I, Double Blind, Placebo-Controlled Study of ZP1848 Administered as Subcutaneous Bolus Injections in Healthy Subjects Followed by Multiple Doses in Patients With Crohn's Disease in Remission

Trial Profile

A Phase I, Double Blind, Placebo-Controlled Study of ZP1848 Administered as Subcutaneous Bolus Injections in Healthy Subjects Followed by Multiple Doses in Patients With Crohn's Disease in Remission

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Glepaglutide (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 22 Nov 2010 Planned number of patients changed from 50 to 66.
    • 22 Nov 2010 Status changed from recruiting to completed.
    • 15 Oct 2010 According to a Zealand Pharma A/S meedia release, this trial showed positive results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top